Myozyme Program Update – Global Version

Category: Archive
January 14, 2009

As Genzyme previously stated in July and again in October 2008, due to greater than expected adoption and rapidly increasing global demand, Myozyme supply will be particularly tight until 4000 L production is approved in the European Union.  Beginning in January inventory levels are expected to be so tight that there is a risk of delays in order fulfillment that could result in potential interruptions to therapy.  To responsibly manage through this temporary supply constraint and best support those currently receiving Myozyme, and in particular to safeguard supply for infants and children, the company has taken a number of steps to ensure optimal management of the existing supply until the 4000 L manufacturing scale is approved by the EMEA.

Please Click Here to Read Full Program Update (PDF, 57 kB).

Back to news articles